News headlines about Zimmer Biomet Holdings (NYSE:ZBH) have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Zimmer Biomet Holdings earned a media sentiment score of 0.08 on Accern’s scale. Accern also gave headlines about the medical equipment provider an impact score of 47.2087112055723 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the news headlines that may have impacted Accern’s rankings:
- Zimmer Biomet Lowered 2017 Guidance Again amid Major Headwinds (finance.yahoo.com)
- Ankle Replacements Take Off as Devices Appear Durable (finance.yahoo.com)
- Zimmer Biomet’s Plan to Revive Growth amid Supply Disruptions (finance.yahoo.com)
- Attractive Product Pipeline Could Revive Zimmer Biomet’s Growth (finance.yahoo.com)
- Key Launches Expected to Drive Zimmer Biomet’s Sales (finance.yahoo.com)
Shares of Zimmer Biomet Holdings (ZBH) traded up $1.15 during trading hours on Wednesday, reaching $112.21. The company’s stock had a trading volume of 1,308,200 shares, compared to its average volume of 1,365,892. The company has a current ratio of 1.47, a quick ratio of 0.78 and a debt-to-equity ratio of 0.88. The stock has a market cap of $22,720.00, a PE ratio of 13.76, a P/E/G ratio of 1.72 and a beta of 1.17. Zimmer Biomet Holdings has a 12 month low of $98.20 and a 12 month high of $133.49.
Zimmer Biomet Holdings (NYSE:ZBH) last issued its earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.74 by ($0.02). Zimmer Biomet Holdings had a net margin of 8.36% and a return on equity of 16.29%. The company had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.83 billion. During the same quarter in the previous year, the company earned $1.79 earnings per share. The firm’s quarterly revenue was down .8% compared to the same quarter last year. analysts predict that Zimmer Biomet Holdings will post 8.03 EPS for the current year.
Several equities analysts have issued reports on ZBH shares. Zacks Investment Research lowered Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. BidaskClub lowered Zimmer Biomet Holdings from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Canaccord Genuity lowered Zimmer Biomet Holdings from a “buy” rating to a “hold” rating and dropped their price target for the stock from $141.00 to $135.00 in a research note on Friday, July 28th. Piper Jaffray Companies restated a “buy” rating and set a $135.00 price target on shares of Zimmer Biomet Holdings in a research note on Friday, July 28th. Finally, Leerink Swann boosted their price target on Zimmer Biomet Holdings from $141.00 to $146.00 and gave the stock an “outperform” rating in a research note on Friday, July 28th. Four investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $133.71.
About Zimmer Biomet Holdings
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.